

## Tagitanlimab

Cat. No.:	HY-P99544
CAS No.:	2417649-97-7
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1][2].

### REFERENCES

- [1]. Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. *Oncologist*. 2019 Feb;24(Suppl 1):S21-S30.
- [2]. Kaplon H, et al. Antibodies to watch in 2023. *MAbs*. 2023 Jan-Dec;15(1):2153410.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA